No quarterly revenue total was found in Cadrenal Therapeutics, Inc.'s SEC filings.
Cadrenal Therapeutics, Inc. (CVKD) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-3.32M
+9.4% vs year-ago quarter
Operating cash flow
$-2.23M
+26.2% vs year-ago quarter
Free cash flow
$-2.57M
-43.3% vs year-ago quarter
EPS
$-1.14
+39.0% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
3.57M
+74.3% vs year-ago quarter
Net cash
$4.36M
Q3 FY2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CVKD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ponte Vedra, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1937993
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.3M | -$2.5M | -$3.1M | -$2.7M | -$3.7M |
| Net income | -$3.3M | -$2.5M | -$3.0M | -$2.7M | -$3.7M |
| Diluted EPS | -$1.14 | -$1.04 | -$1.43 | -$1.31 | -$1.87 |
| Operating cash flow | -$2.2M | -$3.0M | -$2.6M | -$2.4M | -$3.0M |
| Free cash flow | — | — | -$2.6M | -$2.4M | -$3.0M |
| Total assets | $5.6M | $2.9M | $4.3M | $4.1M | $6.0M |
| Total liabilities | $1.5M | $1.1M | $1.6M | $1.4M | $1.7M |
| Stockholders' equity | $4.1M | $1.8M | $2.7M | $2.7M | $4.3M |
| Cash and investments | $2.4M | $2.3M | $4.0M | $3.9M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 29, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 31, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| ARS | Annual report to shareholders | Aug 3, 2026 | Dec 31, 2025 |
All 277 Cadrenal Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.